[Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
In vitro studies of quinolones against intracellular pathogens responsible for lower respiratory tract infections have shown that growth inhibition varies with the strain and with the drug. Following administration of quinolones, drug levels in the lower respiratory tract are similar to or greater than serum levels. Quinolones penetrate readily into cells. The effectiveness of quinolones in lower respiratory tract infections has been demonstrated in both in vitro intracellular infection models and in vivo animal models. These data show that quinolones are a valid therapeutic alternative for lower respiratory tract infections due to intracellular organisms.
Chidiac
C
C
Service Régional des Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, France.
Senneville
E
E
Mouton
Y
Y
D000890:Anti-Infective Agents / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000188:drug therapy; D002939:Ciprofloxacin / Q000627:therapeutic use*; D015365:Enoxacin / Q000627:therapeutic use*; D004917:Erythromycin / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D007877:Legionnaires' Disease / Q000188:drug therapy; D015242:Ofloxacin / Q000627:therapeutic use*; D015366:Pefloxacin / Q000627:therapeutic use*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy
D000890:Anti-Infective Agents; D015366:Pefloxacin; D015365:Enoxacin; D002939:Ciprofloxacin; D004917:Erythromycin; D015242:Ofloxacin
Intérêt des quinolones dans le traitement des infections des voies respiratoires inférieures dues aux germes intracellulaires. A l'exclusion des mycobactéries.